Medina raises $7.7M Series B to fuel neurovascular disease device work; Codman Neuro faces Class I recall for liquid embolic system;

@FierceMedDev: Special Report: 2013's top FDA approvals in med tech. Report | Follow @FierceMedDev

@MarkHFierce: Check out the latest issue of FierceDiagnostics, now with expanded biomarker coverage. Issue | Follow @MarkHFierce

@MichaelGFierce: NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Covidien gets FDA OK for LigaSure laparoscopic surgical device. News | Follow @EmilyWFierce

> California's Medina Medical said it raised $7.7 million in a Series B preferred financing round to propel development of its embolization devices to treat neurovascular disease. Item

> Case Western Reserve University and University Hospitals Case Medical Center are developing a better imaging method to help assess stents placed in coronary arteries. The NIH is fueling the effort with a $1.7 million grant. Item

> The Bay State's Codman Neuro disclosed that the FDA has assigned Class I recall status to its Trufill n-BCA liquid embolic system--the agency's most serious. Codman issued a global medical device correction notice after reports that the mix could solidify too slowly and harm patients. Item

> EndoChoice won Canadian regulatory approval to start marketing its Fuse endoscopy system. Item

> Toronto's Amorfix Life Sciences has inked a deal with "a major global pharmaceutical copany" to use its Alzheimer's disease diagnostic assay in a clinical trial that will test a novel Alzheimer's treatment. Item

Biotech News

@FierceBiotech: The dethroned 'King of Biotech' will stay exiled in prison. News | Follow @FierceBiotech

@JohnCFierce: The 4th quarter was big--Q4 venture haul pushes 2013 biotech investing past $4.5B--and the year was fine, overall. Story | Follow @JohnCFierce

@DamianFierce: Your chance to vote: Who are the most influential people in biopharma today? Survey | Follow @DamianFierce

@EmilyMFierce: ICYMI, yesterday's edition of FierceBiotech Research featured Alzheimer's research and new nanotech. Read | Follow @EmilyMFierce

> Boehringer, Zealand hit reset on GLP-1 diabetes program. More

> U.K. mulls a 'breakthrough' drug program of its own. Article

> Yale researchers chide the FDA for failing to enforce high R&D standards. Coverage

Pharma News

@FiercePharma: What's a $2.9B deal + increasing sales equal? One enthused new CEO at Forest. Yesterday's story | Follow @FiercePharma

@TracyStaton: Here's my story on yesterday's Swiss job shuffle. Story | Follow @TracyStaton

@EricPFierce: Who do you think are the most influential people in biopharma? Like to see someone from manufacturing. Survey | Follow @EricPFierce

@CarlyHFierce: Vivus has lost more than half its board, its CFO, 2 CEOs and 20 staffers--and now its commercial chief, apparently. More | Follow @CarlyHFierce

> Now it's New York: Novartis eyes another 500-plus job cuts with plant shutdown. News

> Appeals court gives GSK another shot at AbbVie in HIV drug-pricing fight. Story

> Sanofi's MS pill Aubagio wins final thumbs-up from U.K. cost-effectiveness watchdogs. More

> Par Pharma nabs injectables specialist JHP for $490M in private-equity auction. Report

Drug Delivery News

> Nano-scaffold delivers genetic treatment to spur blood vessel growth. News

> Biotronik launches drug-releasing balloon Passeo-18 Lux in Europe. Article

> NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story

> Rooted delivery vehicles use electric charge and gravity to release drugs over time. Piece

> Statins delivered with HDL nanoparticles reduce risk of second heart attack, stroke. Story

> Novartis launches joint pain gel in India with Phosphagenics' delivery tech. Item

Diagnostics News

> Researchers from Singapore and China find a new esophageal cancer biomarker. More

> A finger-prick blood test could uncover sports concussions on the field. Article

> Myriad Genetics will market a breast cancer Dx made by a Siemens spinoff. Story

> FDA approves Affymetrix's blood test for developmental disabilities. Coverage

> Illumina brings next-generation sequencing to Amgen companion Dx deal. News

> LabCorp CEO promises continued rollout of new genomics-based Dx tests. Item

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.